Non surgical facial reshaping using MD Codes

Abstract Background Both age‐related and congenital volume deficiencies may be addressed through the injection of hyaluronic acid (HA) fillers. Deep injection provides structural support, more superficial fat‐tissue injection mediates contouring, and superficial intradermal use of HA filler and/or onabotulinumtoxinA may be used for refinement. Aims To evaluate the clinical efficacy, patient satisfaction, and safety of the MD Codes approach as a proposed standardized methodology for full‐face rejuvenation. Methods This was a retrospective, single‐center study of 250 consecutive adult patients undergoing full‐face rejuvenation with HA fillers (Vycross) and onabotulinumtoxinA based on the MD Codes approach. Results The mean age was 39.4 ± 11.6 years, and 80.4% were female. All patients were treated with HA filler in the midface; 89.6% were also treated in the upper face, and 63.2% in the lower face. The mean number of syringes used was 14 ± 4 (range 4‐25), with more syringes typically required in older versus younger patients. All patients received onabotulinumtoxinA treatment. Mean FACE‐Q Appearance‐Related Psychosocial Distress score decreased from 54.3 ± 9.3 pretreatment to 36.1 ± 8.9 at 3 months post‐treatment ( P < .05). The most common complications were bruising (35.2%), transient soft‐tissue edema (14.0%), and prolonged periorbital edema (3.6%). Conclusions Full‐face rejuvenation based on the MD Codes approach provides significant esthetic improvements, with no major safety issues observed.